E. Maillard

5.1k total citations · 2 hit papers
40 papers, 3.3k citations indexed

About

E. Maillard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, E. Maillard has authored 40 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in E. Maillard's work include Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). E. Maillard is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). E. Maillard collaborates with scholars based in France, United States and Ireland. E. Maillard's co-authors include Jean‐Pierre Pignon, Jean Bourhis, Aurélie Le Maître, Laurent Bedenne, Laëtitia Dahan, Jean‐François Seitz, C. Mariette, F. Mornex, Valérie Boige and Denis Pezet and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and The Lancet Oncology.

In The Last Decade

E. Maillard

36 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

2009 2.1k citations Jean‐Pierre Pignon, Aurélie Le Maître et al. Radiotherapy and Oncology profile →
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901

2014 413 citations C. Mariette, Laëtitia Dahan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Maillard France	14	1.8k	1.8k	1.7k	1.1k	331	40	3.3k
M. Alfonsi France	21	2.8k 1.5×	1.8k 1.0×	1.5k 0.9×	1.2k 1.2×	256 0.8×	73	3.5k
John Hay Canada	23	1.3k 0.7×	1.1k 0.6×	948 0.6×	906 0.9×	201 0.6×	58	2.4k
Christoph Glanzmann Switzerland	26	947 0.5×	982 0.6×	1.1k 0.6×	1.0k 1.0×	141 0.4×	59	2.3k
L.J. Peters United States	20	1.2k 0.6×	990 0.6×	592 0.4×	900 0.8×	254 0.8×	45	2.2k
Silke Tribius Germany	27	882 0.5×	861 0.5×	490 0.3×	773 0.7×	351 1.1×	83	2.1k
Fréderic Duprez Belgium	27	1.2k 0.6×	721 0.4×	826 0.5×	625 0.6×	250 0.8×	90	2.3k
Hanne Primdahl Denmark	23	826 0.5×	839 0.5×	520 0.3×	775 0.7×	360 1.1×	63	2.0k
To‐Wai Leung China	29	2.1k 1.1×	1.7k 0.9×	1.2k 0.7×	1.4k 1.4×	313 0.9×	81	3.6k
Mary Ellyn Witt United States	17	997 0.5×	710 0.4×	552 0.3×	607 0.6×	237 0.7×	24	1.5k
Chong‐Jong Wang Taiwan	25	535 0.3×	646 0.4×	599 0.4×	543 0.5×	103 0.3×	56	1.7k

Countries citing papers authored by E. Maillard

Since Specialization

Citations

This map shows the geographic impact of E. Maillard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Maillard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Maillard more than expected).

Fields of papers citing papers by E. Maillard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Maillard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Maillard. The network helps show where E. Maillard may publish in the future.

Co-authorship network of co-authors of E. Maillard

This figure shows the co-authorship network connecting the top 25 collaborators of E. Maillard. A scholar is included among the top collaborators of E. Maillard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Maillard. E. Maillard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Landré, Thierry, E. Maillard, Chérifa Taleb, et al.. (2018). Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. International Journal of Colorectal Disease. 33(8). 1125–1130. 11 indexed citations

Aparicio, Thomas, Olivier Bouché, Julien Taı̈eb, et al.. (2017). Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results. Annals of Oncology. 29(1). 133–138. 50 indexed citations

Rullier, Anne, C. Mariette, E. Maillard, et al.. (2017). Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22). Annals of Oncology. 28. v159–v159. 1 indexed citations

Michel, Pierre, Thierry André, Valérie Boige, et al.. (2017). PRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation. Annals of Oncology. 28. v206–v206.

Michel, Pierre, Valérie Boige, Thierry André, et al.. (2017). Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Digestive and Liver Disease. 50(3). 305–307. 12 indexed citations

Lepage, Côme, Laurent Cany, E. Maillard, et al.. (2016). Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology. 27. vi159–vi159. 3 indexed citations

Aparicio, Thomas, O. Bouché, Éric François, et al.. (2016). Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20. Annals of Oncology. 27. vi194–vi194. 1 indexed citations

Aparicio, Thomas, E. Maillard, Michel Ducreux, et al.. (2016). Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.. Journal of Clinical Oncology. 34(15_suppl). 3532–3532. 1 indexed citations

Bachet, Jean‐Baptiste, Olivier Lucidarme, Julien Taı̈eb, et al.. (2016). FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.. Journal of Clinical Oncology. 34(15_suppl). 3513–3513. 3 indexed citations

10.

Aparicio, Thomas, Éric François, Élisabeth Carola, et al.. (2015). PRODIGE 34 – FFCD 1402 – ADAGE. Digestive and Liver Disease. 48(2). 206–207. 16 indexed citations

11.

Aparicio, Thomas, Olivier Bouché, Éric François, et al.. (2015). PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.. Journal of Clinical Oncology. 33(15_suppl). 3541–3541. 6 indexed citations

12.

Mariette, C., Laëtitia Dahan, F. Mornex, et al.. (2014). Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901. Journal of Clinical Oncology. 32(23). 2416–2422. 413 indexed citations breakdown →

13.

Robb, William B., Laëtitia Dahan, F. Mornex, et al.. (2014). Impact of Neoadjuvant Chemoradiation on Lymph Node Status in Esophageal Cancer. Annals of Surgery. 261(5). 902–908. 61 indexed citations

14.

Boulin, Mathieu, Boris Guiu, E. Maillard, et al.. (2011). Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Digestive and Liver Disease. 43(11). 905–911. 9 indexed citations

15.

Marion, D., et al.. (2010). Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. Gastroentérologie Clinique et Biologique. 34(4-5). 314–318. 5 indexed citations

16.

Bonnetain, Franck, Laëtitia Dahan, E. Maillard, et al.. (2010). Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer. 46(15). 2753–2762. 85 indexed citations

17.

Michiels, Stefan, Aurélie Le Maître, Marc Buyse, et al.. (2009). Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. The Lancet Oncology. 10(4). 341–350. 122 indexed citations

18.

Pignon, Jean‐Pierre, Aurélie Le Maître, E. Maillard, & Jean Bourhis. (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology. 92(1). 4–14. 2125 indexed citations breakdown →

19.

Dupuis, C, et al.. (1970). [Aberrant sub-clavicular arteries in children (20 cases)].. PubMed. 27(9). 917–35. 4 indexed citations

20.

Deminatti, M, et al.. (1968). A propos d'un cas de chromosome X en anneau.. Annales de Génétique. 11(1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact